The goal of this meeting was to generate discussion and move towards consensus on how best to bring long‐acting pre-exposure prophylaxis (PrEP) agents into the clinic for efficacy testing. The meeting included sessions discussing statistical considerations, ethical concerns, and community perspectives on the design of HIV prevention trials for long-acting injectable products.
This meeting took place on May 6th, 2013 in New York.
Materials and links:
Please click on the links below to view the presentations.
For questions or additional information, please contact Kathrine Meyers (email@example.com).